Authored by: Sun Xing , Zhang Wenyi , Zheng Bowen and Zhi Yuan
In July 2024, the Guangdong Provincial Medical Products Administration (hereinafter referred to as “GDMPA”) reported a significant case of smuggling involving unapproved drugs, which has raised substantial attention from the public. This case, notable for its high level of organization and considerable financial implications, is uncommon in recent years. Authorities successfully seized over 5,000 boxes containing more than 80 different types of smuggled drugs, with the total estimated value reaching RMB 200 million. All drugs involved were unapproved for sale within China’s borders and primarily included drugs intended for the prevention and treatment of cancer, as well as the treatment of diabetes and other serious illness.